2017 Speakers

Expand/Collapse

Ed Addison
CEO
Cloud Pharmaceuticals

Ed Addison co-founded Cloud Pharmaceuticals in 2009. Addison is a serial entrepreneur who founded three previous ventures, two of which successfully merged with public companies.  He has a unique and strong blend of in-depth business and technical experience in biotechnology and in information technology. Addison holds an MS in Biomedical Engineering from Johns Hopkins University and MBA from Duke University Fuqua School of Business, including a diploma in Duke’s Health Sector Management Program. From 2000-2009, Addison focused on a series of ventures in the pharmaceutical and life sciences space. These included start-ups in the life sciences market, including BioFortis, a LIMS venture in Baltimore, and Inclinix, a CRO in Wilmington, NC, and TeraDisc, the predecessor of Cloud Pharmaceuticals, where he was named "Coastal Entrepreneur of the Year" in 2009.  Addison has been working in drug discovery and development for over 12 years. As a life sciences business development professional, he has negotiated numerous licenses for therapeutics and technology. He spent the early part of his career in information technology. Addison has been an adjunct professor for over 25 years. Previously he taught at Johns Hopkins University where he developed courses in bioinformatics and entrepreneurship. He was the co-founder and program director of the online MS degree in Bioinformatics for Johns Hopkins University's Whiting School. Addison received prior awards for entrepreneurship including "Entrepreneur of the Year" in 1994 by the Information Industry Association, and #51 on the National Fast 500, and Coastal Entrepreneur of the Year in 2009.  He is the author of a book called Leveraging the Horizon about seed-stage technology ventures

Day Two

Thursday July 27, 2017

14:45 | Discuss: What’s the Future for AI Application and Collaboration and What Can we do Now to Maximize the Chance of Success?

Ron Alfa
Vice President, Discovery & Product
Recursion Pharmaceuticals

Ron holds an MD and a PhD (Neurosciences) from Stanford University and an MA from University College London. Over the course of his education, he has developed molecular therapeutics for Alzheimer's disease, discovered hormones of metabolism, and puzzled over the basis of the placebo effect. A California native, he traded the Valley for the Slopes to follow his passion for accelerating therapeutic discovery with Recursion. When he's not working, Ron enjoys taking on various projects which some might construe as questionably different from working.

Day Two

Thursday July 27, 2017

09:00 | Discover: Massive Parallelization of Rare Disease Drug Discovery

Brandon Allgood
CTO
Numerate

Brandon Allgood, CTO and Co-Founder at Numerate, Inc, manages the development and application of Numerate's AI platform and is responsible for Numerate’s technological vision. Brandon has also served as Director of Computational Science at Numerate and as a Research Scientist at Pharmix. He received a B.S. in Physics from the University of Washington, Seattle, and a Ph.D. in Computational Physics from the University of California, Santa Cruz. Brandon has authored scientific publications in astrophysics, solid-state physics, and computational biology and has 15 years of experience in large scale cloud and distributed computing, AI, and mathematical modeling. He is a member of the Forbes Technology Council and a UCSC Foundation Trustee

Day One

Wednesday July 26, 2017

09:30 | Discover: How AI can be Implemented in Key Areas of Failure Along the R&D Pipeline: A Technology Perspective

Richard Barker
Founding Director
Centre for the Advancement of Sustainable Medical Innovation (CASMI)

Richard is an internationally respected leader in healthcare and life sciences. He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the development and adoption of precision medicine. He also founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK academic initiative aimed at bringing biomedical advances more rapidly and affordably to patients. He is chairman of the South London Health Innovation Network and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease and is a board member of Celgene, a major US-based bio-therapeutics company. His 30-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. The senior roles he has held include: Director General of the Association of the British Pharmaceutical Industry, General Manager of Healthcare Solutions for IBM, Chief Executive of Chiron Diagnostics and head of McKinsey’s European healthcare practice. His book on the future of healthcare ‘2030 - The Future of Medicine: Avoiding a Medical Meltdown’ and his second book ‘Bioscience – lost in translation?’ are published by Oxford University Press.

Day Two

Thursday July 27, 2017

14:45 | Discuss: What’s the Future for AI Application and Collaboration and What Can we do Now to Maximize the Chance of Success?

David Christie
Vice President, Research & Development Informatics
Amgen

At Amgen, David works closely with the head of R&D and the CIO to provide operational and strategic leadership in support of Amgen’s worldwide initiatives in drug discovery and development. Previously, David was Vice President, Global Commercial Operations and Corporate Functions IS. David has also led Amgen’s International IS function based out of Zug, Switzerland, and before that, the IS group supporting Global Development functions. Prior to joining Amgen, David worked at Eli Lilly in various roles in Australia, New Zealand, and the US. David holds a Bachelor of Business from the University of Technology, Sydney.

Day One

Wednesday July 26, 2017

09:00 | Discover: Understanding the Value of AI Application in Pharma R&D

Giancarlo Crocetti
Associate Director, IT-RDM Translational Medicine
Boehringer Ingelheim

Giancarlo Crocetti is an Associate Director for the IT R&D Translational Medicine and Epidemiology at Boehringer Ingelheim and is actively involved in several research areas, including digital health , knowledge search, semantic representation and inference, big data, data, text mining, and network analysis. He is also an Adjunct Full Professor at St. John University where he teaches classes on advanced analytics and is actively involved in research topics eHealth and cognitive science. In his free time, he volunteers with his wife for a not-for-profit organization. He carefully listens to wise experts in any area and tries to put their insight into practice in his daily activities.

Day Two

Thursday July 27, 2017

09:30 | Discover: AI Opportunities in R&D

Shaun Comfort
Associate Director, Senior Safety Science Leader
Genentech

Dr. Comfort is Associate Director for Risk Management and Sr. Safety Science Leader for Roche-Genentech Late Stage Ophthalmology/Hematology Products. He is a Board Certified Neurologist with 13 years combined industry/regulatory experience including roles as former Medical Reviewer at the US FDA, VP of Clinical Research at Anesiva, and CMO for Adaptix Clinical Solutions. Most recently, he has been involved in evaluating Artificial Intelligence solutions for Pharmacovigilance using IBM Watson. He has a broad range of interests and experience including operations research, statistics, and computational physics.

Day Two

Thursday July 27, 2017

14:45 | Discuss: What’s the Future for AI Application and Collaboration and What Can we do Now to Maximize the Chance of Success?

12:00 | Discover: The Low Hanging Fruit that No One Seems to See - Yet: Using AI to Dig Through Your Haystacks of Safety Data

Sally Daub
CEO
Enlitic, Inc.

Sally J. Daub is a CEO, serial entrepreneur, investor, board member and corporate advisor with a track record of turning innovative ideas into market-ready solutions.   Currently the CEO of Enlitic, Sally is driving the deployment and commercialization of Enlitic’s deep learning diagnostic algorithms. Her extensive experience in healthcare and deep technology has been instrumental in building partnerships with clinical and strategic partners to harness data insights and improve patient care in the 21st Century.   As Managing General Partner of Pool Global Partners - a global venture capital fund –  her focus is deep technology including quantum, deep learning and AI technology solutions. A seasoned veteran of multiple boards, including Trillium Health Partners and Hydro One, Sally provides expert guidance to entrepreneurs and boards of both early stage private, and public companies.   An intellectual property lawyer and engineer, Sally’s combination of professional experience and business acumen have been publicly recognized by numerous awards and appointments, including the Women’s Executive Network Top 100 Most Powerful Women (2010, 2011, 2012, 2014), the WXN Hall of Fame (2014), RBC Trailblazer (2010) and Profit Magazine’s Top 100 Entrepreneurs (2010-2014).    

Jun Dong
Director, Global Regulatory Affairs, Development
& Information Technology Services, Sanofi

Jun has a Ph.D. in Physics and done ~10 years researches with 40+ scientific papers published. His has been supporting Big Pharma R&D for more than 18 years. Developed and managed transverse information technology platforms such as Enterprise Application Integration (EAI), Business Process Automation and Monitoring (BPA & BAM), Business Process Management Solutions (BPMS), Application Development Framework (ADF), Application Lifecycle Management (ALM), and all related IT solutions (applications) and services (support). Responsible for maintaining a strategic alignment between business and IT, developing IT project portfolio, planning IT budget, and implementing a roadmap to introduce advanced technologies and solutions and enable business transformation and growth. Accountable for the business satisfaction by delivering innovative IT solutions and services.

Day Two

Thursday July 27, 2017

14:00 | Discuss: Marrying Machine Learning Platforms with R&D Data to Streamline the Application of AI Technology

11:30 | Discover: Cognitive Computing Technology Pilot

Remy Evard
Global CIO
Novartis Institute for BioMedical Research

Day One

Wednesday July 26, 2017

15:30 | Discuss: Revolutionizing Pharmaceutical Culture and Process Towards the Integration of AI

15:00 | Discover: Accelerating the Integration of AI in into Pharmaceutical DNA

Mark Gerstein
Professor, Biomedical Informatics, Molecular Biophysics,
Biochemistry & Computer Science, Yale University

Prof. Mark Gerstein completed his PhD training in Computational Chemistry & Biophysics at Cambridge University, England, followed by postdoctoral training at Stanford. Prof. Gerstein is currently a Professor in the Department of Molecular Biophysics and Biochemistry with a joint appointment in Computer Science and co-director of the Computational Biology & Bioinformatics PhD Program. He is a specialist in bioinformatics with particular interest in large-scale data science, especially as it pertains to personal genome analyses. Current research foci in his lab include cancer genomics, genomic privacy, neurotranscriptomics, biological networks (especially gene regulatory networks), and macromolecular packing. Prof Gerstein has received a number of awards such as being elected as a fellow of the AAAS and the ISCB (International Society of Computational Biology).

Day Two

Thursday July 27, 2017

13:30 | Discover: Harnessing AI to Make Sense of Large, Complex Datasets and Re-Invigorate R&D Innovation

Peter Henstock
Senior Manager
Pfizer

Peter Henstock is working to transform Pfizer using AI and Machine Learning.  He is a Sr. Manager in the Business Technology group in Massachusetts dividing time between running software projects, developing data analysis methodologies, and creating visualization/analysis software solutions. He holds a Ph.D. in Artificial Intelligence from Purdue University and Master’s degrees in Biology, Software Engineering, Statistics, Applied Linguistics, and Image Processing.  Before joining Pfizer, Peter worked at MIT Lincoln Laboratory in image processing and computational linguistics. He also teaches graduate level Machine Learning & Data Mining and Software Engineering at Harvard University.

Day One

Wednesday July 26, 2017

14:30 | Discover: Why Has AI Been MIA in Pharma & What Can it Do for Us Today?

12:45 | Discuss: Discussing the Collision of Two Powerhouse Industries to Harmonize AI Application in the Pharmaceutical Industry

Chih-Ming Ho
CTO
KYAN Therapeutics

Chih-Ming Ho received Ph.D. from The Johns Hopkins University.  His specialties include personalized medicine and microfluidics for bio diagnosis.  In 1997, Dr. Ho was inducted as a member of the US National Academy of Engineering. The membership is one of the highest professional honors accorded an engineer.  In the next year, he was elected as an Academician of Academia Sinica, which honors scholars of Chinese origin with exceptional achievements in liberal arts and sciences.  In 2014, Dr. Ho received Doctor of Engineering Honoris Causa from Hong Kong University of Science and Technology. Dr. Ho holds ten honorary chair professorships including the Einstein Professorship from Chinese Academy of Science.  Dr. Ho was elected Fellow of APS, AAAS, AIMBE and AIAA.

Day One

Wednesday July 26, 2017

12:15 | Discover: Artificial Intelligence for Personalized Medicine

12:45 | Discuss: Discussing the Collision of Two Powerhouse Industries to Harmonize AI Application in the Pharmaceutical Industry

Shahar Keinan
CSO
Cloud Pharmaceuticals

Shahar Keinan received her Ph.D. from The Hebrew University of Jerusalem in Israel, followed by a Post Doctoral Fellowships at Northwestern University and Duke University where she was one of the inventors of Quantum Molecular Design Technology. Subsequently she joined Ed Addison and Lawrence Husick to found Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry and has published over 40 papers and presentations in the fields of in-silico drug design and discovery.

Day Two

Thursday July 27, 2017

14:00 | Discuss: Marrying Machine Learning Platforms with R&D Data to Streamline the Application of AI Technology

10:00 | Discover: Showcasing the Utility of AI in Early Stages of R&D to Prove This Disruptive Technology’s Validity

Jinhan Kim
CEO
Standigm

Experience May 2015 – Present Standigm CEO & Co-founder Seoul, Korea Aug 2012 – Apr 2015 Samsung Advanced Institute of Technology (Samsung Group's R&D hub) Senior Research Scientist Suwon, Korea Jun 2002 – Apr 2004 NCSOFT Software Developer Seoul, Korea   Education 2008 - 2012 The University of Edinburgh PhD, Artificial Intelligence Edinburgh, UK 2005 – 2008 Seoul National University MSc, Artificial Intelligence Seoul, Korea 1995 – 2001 Seoul National University BSc, Applied Biology and Chemistry Seoul, Korea  

Day One

Wednesday July 26, 2017

10:00 | Discover: Artificial Applicable Intelligence in Drug Discovery and Repositioning

Guido Lanza
CEO
Numerate

Guido Lanza is the President and CEO of Numerate. Formerly, Guido was the co-founder and Chief Technical Officer of Pharmix, where he served on the company's Board of Directors for five years and was named one of Business Week's "Tech's Best Young Entrepreneurs under-30" in 2006. Prior to Pharmix, Guido was a research scientist with Professor Koza of Stanford University with whom he developed applications of genetic programming in the area of bioinformatics and computational biology. Guido is the author of 10 scientific publications and inventor of 4 issued patents. He received a B.A. in Molecular and Cell Biology and Integrative Biology from the University of California, Berkeley and an M.Sc. in Bioinformatics from the University of Manchester (UK).

Day One

Wednesday July 26, 2017

10:10 | Discuss: How AI Technology can Accelerate, Cheapen and De-Risk R&D

Ray Liu
Senior Director & Head, Statistical Innovation & Consultation
Takeda

Dr. Ray Liu is the Sr. Director and Head of Statistical Innovation and Consultation group at Takeda Pharmaceutical Company with responsibility to develop novel statistical methodology, and provide statistical consultation and project support to various functional areas in R&D, including Discovery, CMC, Translational Research, and Outcome Research.   Ray is an active contributor in the statistical community. He was the conference chair of Midwest Biopharmaceutical Statistics Workshop for years 2015 and 2016, and has served at the organizing committee and as session chairs for various conferences, including NCB, ICSA and JSM meetings. He is the author of more than 30 statistical and scientific manuscripts and book chapters, and is the member of ASA, PSTC Stats working group, IQ consortium, and NCBLF.   Dr. Ray Liu received his bachelor and master degrees from National Taiwan University and PhD degree from Columbia University. His current research interests are big data, text mining and joint analysis of hi-dimensional data.

Day One

Wednesday July 26, 2017

15:30 | Discuss: Revolutionizing Pharmaceutical Culture and Process Towards the Integration of AI

Armaghan Naik
Director & Head, Design Sciences
Sanofi

After graduating with a BS in Computational Biology from Carnegie Mellon, Rumi worked at Intel Corporation in pre-silicon validation teams in both Portland, OR and Hudson, MA where he specialized in writing machine checked formal proofs of correctness of control and datapath circuits from Pentium 4s (130nm and later) to the Nehalem-class Core i7s, and several server processors. At Carnegie Mellon, in his PhD studies and as a Lane Postdoctoral Fellow, Rumi has focused on problems in the automation of biological research, spanning from machine learning method development in active learning, to laboratory automation of mammalian cell culture and microscopy. Now at Sanofi Pasteur, Rumi is a Director in the Innovation and External Networks group (InnX), and focused on developing novel machine learning-based approaches to accelerate the entire vaccine development pipeline.

Day One

Wednesday July 26, 2017

10:10 | Discuss: How AI Technology can Accelerate, Cheapen and De-Risk R&D

Jason Raines
Head, Biometrics Data Sciences & Operations
Biogen

Jason currently serves at the Head, Biometrics Data Sciences and Operations at Biogen.  This Biometrics function comprises Global Clinical Data Management, Biometrics Quality, Biometrics Operations, Standards and Governance, and Data Analytics Innovation. Jason has over 21 years experience in clinical research.  Over the course of his career, Jason lead the development of best in class Data Management and Statistical Programming organizations and implemented globally deployed clinical technologies. Prior to joining Biogen, Jason’s last role at Novartis was  Head, Global Data Operations which included Clinical Data Management, Statistical Programming, Clinical Systems, and Standards and worked as the R&D IT Portfolio Coordinator responsible for oversight and administration of all R&D IT related activities. As well, Jason served as the Novartis EDC/CDMS modernization steering committee chair and was an active member in Novartis cross-divisional work streams responsible for developing Digital, Real World Evidence, Big Data, and Clinical Data and Reporting Transformation strategies. Jason holds Bachelor’s and Master’s of Science degrees from the University of Texas, and a Master’s degree in Biostatistics from the University of North Texas Health Science Center. Jason is a frequent speaker and contributor to Data Management and Statistical Programming focused conferences

Pre-Conference Workshop B

Tuesday, July 25 2017

12:00 | A Fundamental Guide to the Application of AI in Clinical Trials to Reduce Failure Rates

Leonardo Rodrigues
Associate Director, Advanced Analytics
BERG

Dr. Rodrigues, Ph.D., is an Associate Director of Advanced Analytics at Berg Analytics, a division of Berg Pharma. As the first scientist of Berg Analytics he designed the architecture and was the first developer of most algorithms in production. Currently, Dr. Rodrigues leads the research, development and internalization of innovative analytical methodologies and IT platforms. With more than 15 years of experience in data analysis and biology research, Dr. Rodrigues has as expertise in streamlining innovations that translate data into actionable solutions. Prior, as a Postdoc at the Whitehead Institute-MIT, he combined computational, molecular and cell biology to study the molecular basis of tumor metastasis.

Day One

Wednesday July 26, 2017

12:45 | Discuss: Discussing the Collision of Two Powerhouse Industries to Harmonize AI Application in the Pharmaceutical Industry

11:45 | Discover: Showcasing the Application of AI to Unravel Human Disease Complexity

Ranga Sarangarajan
Senior Vice President & CSO
BERG

Dr. Sarangarajan is the Senior Vice President & Chief Scientific Officer at BERG oversees all research & development activities. He is the co-inventor and co-architect of the BERG Interrogative Biology® technology and leads the implementation of scientific strategies and overall operations of the multifunctional integrated scientific program intersecting science and technology. He is responsible for developing strategies for rapid validation of preclinical and translation into clinical development and beyond of drug targets, therapeutics and biomarkers in the areas of cancer, cardiovascular and metabolic diseases, neurological diseases and other area(s) of BERG focus. Dr. Sarangarajan’s education as a pharmacist and his diversity in graduate training provided the scientific acumen and knowledge base for diligent implementation of the fundamental tenets underlying the BERG Interrogative Biology® platform and the appropriate translation of its outputs in creation of the diverse BERG program pipeline. At the Massachusetts College of Pharmacy and Health Sciences (MCPHS), he oversaw the implementation of an integrated biological sciences program that intersected the basic sciences to clinical outcomes within the pharmacy curriculum. The transition to BERG provided Dr. Sarangarajan the opportunity to translate the concepts of study of integrating biological systems to drug discovery and development. Dr. Sarangarajan has numerous US and international pending patent applications, covering areas of discovery platform, cancer, metabolic diseases, diabetes, obesity and diagnostics. He has published extensively and has presented his research in national and international medical and scientific meetings. He co-authored and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the role of mitochondrial function and metabolic network regulation in the etiology of cancer as it pertains to the seminal observations made by Otto Warburg. Dr. Sarangarajan is a member of numerous professional organizations and has served in various capacities including the New England Society of Cosmetic Chemists, the Society of Toxicology, American Society for Pharmacology & Experimental Therapeutics, American Association of Colleges of Pharmacy and has been a reviewer for many scientific journals in the areas of pharmacology & toxicology. Dr. Sarangarajan received his B.S. in Pharmacy from Maharaja Sayajirao University (India) and a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati College of Pharmacy. He received post-doctoral training at the University of Cincinnati Children’s Hospital Research Foundation and Department of Dermatology prior to moving to MCPHS.  

Day One

Wednesday July 26, 2017

17:45 | Chair's Closing Remarks

08:50 | Chair's Opening Remarks

Day Two

Thursday July 27, 2017

15:45 | Chair’s Closing Remarks

08:50 | Chair's Opening Remarks

Jeremy Sohn
Vice President, Global Head of Digital Business
Development & Licensing, Novartis

Jeremy joined Novartis in 2015 as VP, Head of Digital Business Development & Licensing supporting Novartis’ Digital Medicines program. In 2016, Jeremy has also served as Global Head of Digital Development within Novartis Global Development Organization. Jeremy is a serial software entrepreneur with more than 15 years of experience founding and managing healthcare and technology companies. Prior to Novartis, Jeremy was Managing Director at MPM Capital where he led the firm's digital-health investment strategy. At MPM, Jeremy founded two companies, CentrosHealth (acquired by Clinical Ink) and TriNetX. In 2011, Jeremy co-founded GrapeVine, a software company that optimizes how organizations connect with their target communities. From 2007-2011, Jeremy was COO and VP, Strategy & Corporate Development for North Plains Systems, where he lead the company's growth and eventual sale to Accel-KKR. In 2000, he co-founded an open-source operating system company, Wasabi Systems.
 

Day One

Wednesday July 26, 2017

15:30 | Discuss: Revolutionizing Pharmaceutical Culture and Process Towards the Integration of AI

15:00 | Discover: Accelerating the Integration of AI in into Pharmaceutical DNA

Hal Stern
Executive Director, Applied Technology
Merck

Hal Stern is Executive Director of Applied Technology at Merck, where his group builds disruptive services and architectures for healthcare information technology, making big data more useful, privacy and consent management and improved precision computing.  His group’s current work includes using blockchain to improve transparency and federation of health care data, fine grain real time data entitlements, applications of graph algorithms to scientific data domains, using machine learning to discover subtle relationships including privacy constraints, and looking at new approaches to computationally hard problems. Hal was previously a VP at Juniper Networks and spent more than 20 years at Sun Microsystems in a variety of technical leadership roles. He earned a BSE degree in Electrical Engineering and Computer Science from Princeton University and holds eight patents in the areas of security, identity, user experience, and networking. Hal has been a frequent speaker at industry and technical conferences, and has co-authored three technical books. He serves on the Princeton University CIO Advisory Council, the board of the Microfinance Information Exchange, and the Graduate Board of the Colonial Club of Princeton University.  He is an active Kiva microlender and digital photographer, and may be found outside of work coaching the NJ Devils Youth Hockey U8 teams, playing bass guitar, or golfing very badly.

Day One

Wednesday July 26, 2017

10:10 | Discuss: How AI Technology can Accelerate, Cheapen and De-Risk R&D

Day Two

Thursday July 27, 2017

11:00 | Discover: Making Big Data Useful: Practical Approaches

Zeeshan Syed
Director, Clinical Inference & Algorithms Program
Stanford Health Care

Zeeshan Syed is the Inaugural Director of the Clinical Inference and Algorithms Program at Stanford Health Care and a Clinical Associate Professor at the Stanford University School of Medicine. Before joining Stanford in 2016, Dr. Syed was an Associate Professor with Tenure in Computer Science and Engineering at the University of Michigan, where he was a Principal Investigator for the Artificial Intelligence Laboratory and led the Computational Biomarker Discovery and Clinical Inference Group. Dr. Syed received SB and MEng degrees in Electrical Engineering and Computer Science at MIT, and a PhD through a joint program between MIT’s School of Engineering and Harvard Medical School in Computer Science and Biomedical Engineering. Dr. Syed’s research investigates the design and application of advanced healthcare-specialized machine learning and artificial intelligence technologies for clinical effectiveness, high-value care and population health, and has featured at top machine learning and artificial intelligence conferences (NIPS, ICML, AAAI, KDD) as well as in the media (Wired, CBS, NPR, WSJ, Technology Review, ZDNet). Dr. Syed is the recipient of multiple national awards for his scholarship activities, including the prestigious CAREER award from the National Science Foundation. Dr. Syed is also actively engaged with the healthcare analytics industry, having been part of the core early-stage team for the Google[X] Life Sciences initiative (now Verily) and as a founder of HEALTH[at]SCALE Technologies.

Pre- Conference Workshop A

Tuesday, July 25 2017

09:00 | AI for Precision Medicine: Harnessing AI Technology to Provide More Granular and Valuable Insights on Patients and Healthcare

Alex Zhavoronkov
CEO
Insilico Medicine

Pre- Conference Workshop C

Tuesday, July 25 2017

15:00 | A Fundamental Guide to the Application of AI in Drug Discovery to Uncover the Next Wave of Successful Future Candidates